Placeholder Banner

BIO Applauds Reps. Sean Duffy and John Carney for Introducing the Corporate Governance Reform and Transparency Act

May 25, 2016

Bill would foster accountability, transparency and competition in proxy advisory firm industry

Washington, D.C. (May 25, 2016) – Today, the Biotechnology Innovation Organization (BIO) applauds Reps. Sean Duffy (R-WI) and John Carney (D-DE) for introducing the Corporate Governance Reform and Transparency Act.

The bill would require proxy advisory firms to be more transparent and open to input in their standard-setting process.  It would also ensure that firms have the resources necessary to provide accurate recommendations on emerging companies as well as processes in place to manage potential conflicts of interest.  Under the bill, firms would be encouraged to engage in a dialogue with the companies impacted by their recommendations.

The following statement may be attributed to BIO President & CEO Jim Greenwood:

“Emerging biotech companies on the public market operate in a unique industry that values a strong relationship with investors, yet they often are held by proxy advisory firms to one-size-fits-all standards that are not applicable to their business and are forced to engage in proxy fights over issues that do not add value for shareholders.  These issues are exacerbated by the conflicts of interest inherent in some of the firms’ business models. 

“BIO commends Reps. Duffy and Carney for introducing the Corporate Governance Reform and Transparency Act to enhance transparency and accountability in the proxy firm industry.  This important legislation would allow growing biotech companies to focus on advancing their clinical research and achieving company growth that benefits both shareholders and patients.”

Since the JOBS Act became law four years ago, more than 190 biotechs have gone public as emerging growth companies (EGCs).  BIO supports legislation, like the Corporate Governance Reform and Transparency Act, that supports these newly public companies by reducing roadblocks that divert company focus, time and funds to non-R&D distractions that can slow the development of groundbreaking medicines.


Upcoming BIO Events 

BIO International Convention
June 6-9, 2016
San Francisco, CA

BIO Latin America Conference
October 26-28, 2016
São Paulo, Brazil

BIO Investor Forum
October 18-19, 2016
San Francisco, CA

Animal Biotech Summit
September 21-23, 2016
Bethesda, MD


###

Discover More
Today, the Biotechnology Innovation Organization (BIO) submitted its comments in response to the U.S. Department of Agriculture’s (UDSA) Solicitation of Input from Stakeholders on Agricultural Innovations, part of the Department’s Agriculture…
Washington, D.C. (July 29, 2020) – The Food and Agriculture Section of the Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Board leadership. Sylvia Wulf, CEO of AquaBounty Technologies, Inc., and Brian…
Says biopharma researchers and scientists stand ready to support real solutions that will address patient drug costs, continue lifesaving science Dr. Michelle McMurry-Heath, the president and CEO of the Biotechnology Innovation Organization (BIO),…